Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib study of limited androgen ablation and two dose levels of temsirolimus (NSC 683864) in patients with prostate cancer who have a biochemical relapse after prostatectomy and/or radiotherapy

Trial Profile

Phase Ib study of limited androgen ablation and two dose levels of temsirolimus (NSC 683864) in patients with prostate cancer who have a biochemical relapse after prostatectomy and/or radiotherapy

Discontinued
Phase of Trial: Phase I

Latest Information Update: 04 Jan 2013

At a glance

  • Drugs Temsirolimus (Primary) ; Bicalutamide; Flutamide; Goserelin; Leuprorelin; Nilutamide
  • Indications Prostate cancer
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 02 Jul 2010 Planned end date (Jan 2008) added as reported by ClinicalTrials.gov.
    • 02 Jul 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top